Impact of metformin versus repaglinide on non-glycemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes

S.S. Lund*, L. Tarnow, C.D.A. Stehouwer, C.G. Schalkwijk, T. Teerlink, J. Gram, K. Winther, M. Frandsen, U.M. Smidt, O. Pedersen, H.H. Parving, A.A. Vaag

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Objective: In patients with type 2 diabetes mellitus (T2DM), biomarkers reflecting inflammation and endothelial dysfunction have been linked to cardiovascular disease (CVD biomarkers) and metabolic regulation. In T2DM patients, metformin and insulin secretagogues have demonstrated equal anti-hyperglycaemic potency. Here, we report the effect of metformin versus an insulin secretagogue, repaglinide, on CVD biomarkers in non-obese T2DM patients. Design and methods: Single-centre, double-masked, double-dummy, crossover study during 2x4 months involving 96 non-obese (body mass index
Original languageEnglish
Pages (from-to)631-41
JournalEuropean Journal of Endocrinology
Publication statusPublished - 1 Jan 2008

Cite this